IV Carnexiv carbamazepine regulatory update

H. Lundbeck said FDA accepted for review a resubmitted NDA for IV Carnexiv carbamazepine to treat epilepsy in patients who temporarily cannot take their oral carbamazepine. The company expects an FDA ...